Parmodia Dosage/Direction for Use

Patients should be on a lipid-lowering diet before the initiation of PARMODIA, and should continue dietary control during treatment. Serum lipid levels should be monitored periodically. If an adequate response has not been achieved, complementary or different therapeutic measures should be considered.
Posology: Adult: The usual adult dose is 0.1 mg twice daily. The dose may be individualized according to the patient's age and symptoms. The maximum dose is 0.2 mg twice daily.
Elderly: Since elderly patients often have reduced physiological function, PARMODIA should be carefully administered with close monitoring for signs of adverse reactions and clinical status of the patient.
Pediatric population: The safety of PARMODIA in low birth weight infants, newborns, infants, and children has not been established. No data are available.
Patients with renal impairment: PARMODIA should be used with caution in patients with renal impairment defined as estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73 m². A lower starting dose or prolonged dosing intervals should be considered. The maximum dose is 0.2 mg daily (see PHARMACOLOGY: Pharmacokinetics under Actions).
Patients with hepatic impairment: PARMODIA should be used with caution in patients with hepatic disorder (Child-Pugh grade A cirrhosis, etc.) or a history of hepatic disorder. Dose reduction should be considered as necessary (see PHARMACOLOGY: Pharmacokinetics under Actions).
PARMODIA is contraindicated in patients with severe hepatic disorder, Child-Pugh grade B or C cirrhosis, or biliary obstruction (see Contraindications and PHARMACOLOGY: Pharmacokinetics under Actions).
Method of administration: PARMODIA should be taken orally twice daily in the morning and evening. PARMODIA can be taken without regard to meals.
The tablet can be divided into equal halves.